McGill Newsroom

Canadian drug safety network provides reassuring evidence regarding risk of heart failure of anti-diabetes medications

Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study published in the New England Journal of Medicine.

Classified as: drugs, jewish general hospital, diabetes, Lady Davis Institute (LDI), Canadian Institutes of Health Research (CIHR), health and lifestyle, New England Journal of Medicine, Heart failure, incretin, Canadian Network for Observational Drug Effect Studies, Drug Safety and Effectiveness Network
Published on: 24 Mar 2016
Back to top